Osprey Medical, Inc., a commercial stage company, provides contrast reduction and monitoring technologies in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.95|
|52 Week High||AU$0.76|
|52 Week Low||AU$2.80|
|1 Month Change||21.80%|
|3 Month Change||-40.63%|
|1 Year Change||-63.46%|
|3 Year Change||-95.13%|
|5 Year Change||-97.71%|
|Change since IPO||-97.74%|
Recent News & Updates
|OSP||AU Medical Equipment||AU Market|
Return vs Industry: OSP underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: OSP underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: OSP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: OSP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Osprey Medical, Inc., a commercial stage company, provides contrast reduction and monitoring technologies in the United States and internationally. It offers AVERT, AVERT Plus, DyeVert NG, DyeVert Plus System, and DyeVert Plus EZ Systems, which are used to protect patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures. The company was incorporated in 2005 and is headquartered in Minnetonka, Minnesota.
Osprey Medical Fundamentals Summary
|OSP fundamental statistics|
Is OSP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSP income statement (TTM)|
|Cost of Revenue||US$1.31m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-573.52%|
How did OSP perform over the long term?See historical performance and comparison
Is Osprey Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OSP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OSP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OSP is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: OSP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OSP is good value based on its PB Ratio (1.9x) compared to the AU Medical Equipment industry average (5x).
How is Osprey Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Osprey Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Osprey Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSP is currently unprofitable.
Growing Profit Margin: OSP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSP is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare OSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: OSP has a negative Return on Equity (-114.17%), as it is currently unprofitable.
How is Osprey Medical's financial position?
Financial Position Analysis
Short Term Liabilities: OSP's short term assets ($12.1M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: OSP's short term assets ($12.1M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: OSP's debt to equity ratio (11.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if OSP's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OSP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.2% each year
What is Osprey Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike McCormick (59 yo)
Mr. Michael McCormick, also known as Mike has been the President and Chief Executive Officer of Osprey Medical Inc. since March 2010. Mr. McCormick has more than 20 years of experience in the medical devic...
Experienced Management: OSP's management team is seasoned and experienced (10.3 years average tenure).
Experienced Board: OSP's board of directors are considered experienced (9.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 71.2%.
Osprey Medical, Inc.'s employee growth, exchange listings and data sources
- Name: Osprey Medical, Inc.
- Ticker: OSP
- Exchange: ASX
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$24.376m
- Shares outstanding: 25.66m
- Website: https://www.ospreymed.com
- Osprey Medical, Inc.
- 5600 Rowland Road
- Suite 250
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:28|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.